Ohm, have any thought on GLSI? "If the patient
Post# of 150907
"If the patient completed the Primary Immunization Serie, the 5-year disease-free survival rate in the 46 HER2 3+ patients treated with GLSI-100 was 100% versus 89.4% in the 50 placebo patients treated with GM-CSF"
https://markets.businessinsider.com/news/stoc...1031036746

